Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From genes to drugs: targeted strategies for melanoma.
Flaherty KT, Hodi FS, Fisher DE. Flaherty KT, et al. Among authors: hodi fs. Nat Rev Cancer. 2012 Apr 5;12(5):349-61. doi: 10.1038/nrc3218. Nat Rev Cancer. 2012. PMID: 22475929 Review.
Modeling genomic diversity and tumor dependency in malignant melanoma.
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Lin WM, et al. Among authors: hodi fs. Cancer Res. 2008 Feb 1;68(3):664-73. doi: 10.1158/0008-5472.CAN-07-2615. Cancer Res. 2008. PMID: 18245465 Free PMC article.
Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Hodi FS, et al. J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707. J Clin Oncol. 2008. PMID: 18421059 No abstract available.
Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Jiang X, et al. Among authors: hodi fs. Clin Cancer Res. 2008 Dec 1;14(23):7726-32. doi: 10.1158/1078-0432.CCR-08-1144. Clin Cancer Res. 2008. PMID: 19047099
Mutation-driven drug development in melanoma.
Flaherty KT, Hodi FS, Bastian BC. Flaherty KT, et al. Among authors: hodi fs. Curr Opin Oncol. 2010 May;22(3):178-83. doi: 10.1097/cco.0b013e32833888ee. Curr Opin Oncol. 2010. PMID: 20401974 Free PMC article. Review.
Advances in targeted therapy for melanoma.
Friedlander P, Hodi FS. Friedlander P, et al. Among authors: hodi fs. Clin Adv Hematol Oncol. 2010 Sep;8(9):619-27. Clin Adv Hematol Oncol. 2010. PMID: 21157411 Review.
391 results